BRAF mutations conferring resistance to BRAF inhibitors
US8637246B2 · kind B2 · utility
0Cited by
84References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2011 |
| Grant date | Jan 28, 2014 |
| Priority date | — |
| Expiry date | Feb 22, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.